Research Analysts’ Weekly Ratings Changes for Insmed (INSM)

A number of firms have modified their ratings and price targets on shares of Insmed (NASDAQ: INSM) recently:

• 2/24/2026 – Insmed had its price target lowered by Mizuho from $211.00 to $204.00. They now have an “outperform” rating on the stock.
• 2/23/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright. They now have a $230.00 price target on the stock.
• 2/20/2026 – Insmed was given a new $166.00 price target by Morgan Stanley.
• 2/20/2026 – Insmed had its price target lowered by Wells Fargo & Company from $234.00 to $208.00. They now have an “overweight” rating on the stock.
• 2/19/2026 – Insmed was given a new $205.00 price target by Stifel Nicolaus.
• 2/19/2026 – Insmed was given a new $211.00 price target by Mizuho.
• 1/30/2026 – Insmed had its price target raised by Morgan Stanley from $157.00 to $162.00. They now have an “equal weight” rating on the stock.
• 1/27/2026 – Insmed is now covered by Barclays PLC. They set an “overweight” rating and a $231.00 price target on the stock.
• 1/27/2026 – Insmed is now covered by Barclays PLC. They set an “overweight” rating and a $231.00 price target on the stock.
• 1/23/2026 – Insmed was upgraded by Roth Mkm to “strong-buy”.
• 1/22/2026 – Insmed is now covered by Roth Mkm. They set a “buy” rating and a $212.00 price target on the stock.
• 1/22/2026 – Insmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/21/2026 – Insmed had its price target raised by Royal Bank Of Canada from $197.00 to $200.00. They now have an “outperform” rating on the stock.
• 1/12/2026 – Insmed was given a new $205.00 price target by Truist Financial Corporation.
• 1/8/2026 – Insmed was given a new $157.00 price target by Morgan Stanley.
• 1/6/2026 – Insmed had its price target lowered by UBS Group AG from $223.00 to $215.00. They now have a “buy” rating on the stock.

Insider Activity at Insmed

In other Insmed news, COO Roger Adsett sold 791 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at approximately $16,680,517.70. This trade represents a 0.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $150.97, for a total value of $1,615,228.03. Following the completion of the sale, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $45,469,899.45. This trade represents a 3.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 178,952 shares of company stock valued at $30,222,170 over the last three months. 3.00% of the stock is owned by company insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.